PORTFOLIO CMC ADVISORS

Most Phase 2 manufacturing failures weren't created in Phase 2.

They were already present — quietly —…

THE PROBLEM

The gap you can't see is the one that scales.

Biotech programs are financed and managed around visible clinical progress. Manufacturing understanding matures more slowly and far less visibly — so for a stretch of development, enterprise exposure and process understanding drift apart without anyone deciding to let them.

Early success makes it worse, not better: repeated batch success gets read as proof of readiness, when what it usually proves is feasibility inside a narrow operating window. The window holds — right up until scale, tech transfer, and distributed execution test its edges all at once, at exactly the moment the most is riding on the program. The failure looks sudden. It almost never is.

THE FRAMEWORK

A framework for seeing it earlier.

The Phase 2 Manufacturing Wall™ is a framework for understanding how hidden manufacturing fragility becomes enterprise risk as programs scale — why organizations miss the warning signs, and where the earlier intervention window actually sits. It's written for the people who carry that exposure: executive teams, investors, boards, and the CMC leaders who see the fragility first. Co-authored with Bharat Gurale, Ph.D.

Read the white paper →

MANUFACTURING RISK ASSESSMENT

Locate your own program.

The Manufacturing Risk Assessment is a short self-assessment that explores your program’s Readiness–Exposure Gap™—how deeply the manufacturing process is understood relative to how much the enterprise now depends on it.

It doesn't grade you, and it won't tell you you're failing. It shows you where exposure may be outrunning understanding, while looking is still inexpensive.

Take the Manufacturing Risk Assessment →

THE COST OF LATE RESOLUTION™

What does waiting cost your program?

Unresolved manufacturing uncertainty can compress schedules, consume capital, narrow options, and erode enterprise value. The Cost of Late Resolution™ examines six mechanisms through which resolving uncertainty late becomes a business problem.

Explore the white paper, then use the Business Exposure Assessment — Lite to examine how manufacturing readiness could affect your next program or business objective.

Read the white paper →

Take the Business Exposure Assessment — Lite →

WHO'S BEHIND THIS

Lonnie Robarge, Ph.D.

I've spent 25+ years in small-molecule CMC and process development, operating where manufacturing, development, and business strategy meet — long enough to watch the same pattern repeat across very different companies. A program advances cleanly, the clean run gets read as readiness, and the manufacturing fragility that was there the whole time only surfaces once the enterprise has scaled around the assumption that it wasn't. I've been in the room for the good version of this — three FDA approvals, registration-scale supply, an 85% reduction in cost of goods — and for the hard version, where the gap surfaces late and expensive. The Phase 2 Manufacturing Wall is my attempt to name that pattern precisely enough that it can be seen, and acted on, before the cost compounds.

Through Portfolio CMC Advisors, I work with executive teams, investors, and boards on manufacturing-readiness reviews, fractional CMC leadership, board- and investor-level diligence, and CDMO network strategy — usually at the moments when exposure is about to step up: a financing event, a tech transfer, a scale-up.

25+ yrs

Small-molecule CMC & process development

3

FDA approvals supported

85%

Reduction in cost of goods delivered

4

Advisory engagement types, exec to board

If your program is approaching a financing event, a tech transfer, or a scale-up — and you want a clear-eyed read on the manufacturing exposure underneath it — let's talk.

PORTFOLIO CMC ADVISORS

lrobarge@portfoliocmc.com

© 2026 Lonnie Robarge. The Phase 2 Manufacturing Wall™ and the Readiness–Exposure Gap™ are trademarks of Portfolio CMC Advisors. All rights reserved.